Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bewertung von SPN-812 (Viloxazin-Kapsel mit verlängerter Freisetzung) bei Kindern im Vorschulalter mit ADHS

2. Oktober 2026 aktualisiert von: Supernus Pharmaceuticals, Inc.

Eine randomisierte, doppelblinde, multizentrische, placebokontrollierte Parallelgruppenstudie der Phase 4 zur Wirksamkeit und Sicherheit von SPN-812 bei Kindern im Vorschulalter (4 bis 5 Jahre) mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Studienübersicht

Detaillierte Beschreibung

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Studientyp

Interventionell

Einschreibung (Geschätzt)

286

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Alabama
      • Saraland, Alabama, Vereinigte Staaten, 36571
    • Arkansas
      • Fayetteville, Arkansas, Vereinigte Staaten, 72703
        • Zurückgezogen
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Vereinigte Staaten, 72211
    • California
      • Anaheim, California, Vereinigte Staaten, 92805
        • Rekrutierung
        • Advanced Research Center (ARC), Inc.
        • Kontakt:
      • Encino, California, Vereinigte Staaten, 91316
        • Zurückgezogen
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Vereinigte Staaten, 92844
        • Beendet
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Vereinigte Staaten, 92251
      • Long Beach, California, Vereinigte Staaten, 90807
      • Newport Beach, California, Vereinigte Staaten, 92660
        • Zurückgezogen
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Vereinigte Staaten, 80112
        • Rekrutierung
        • IMMUNOe Research Centers
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 303-773-9000
    • Florida
      • Clermont, Florida, Vereinigte Staaten, 34711
        • Zurückgezogen
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Vereinigte Staaten, 33134
        • Rekrutierung
        • Luna Research Center
        • Kontakt:
          • Telefonnummer: 305-613-7761
      • Gainesville, Florida, Vereinigte Staaten, 32607
        • Beendet
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Vereinigte Staaten, 32256
        • Rekrutierung
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Telefonnummer: 904-281-5757
      • Lakeland, Florida, Vereinigte Staaten, 33803
        • Beendet
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Vereinigte Staaten, 33155
      • Orange City, Florida, Vereinigte Staaten, 32763
        • Rekrutierung
        • Medical Research Group of Central Florida
        • Kontakt:
          • Telefonnummer: 386-775-7627
      • Orlando, Florida, Vereinigte Staaten, 32801
      • Orlando, Florida, Vereinigte Staaten, 32803
        • Rekrutierung
        • APG Research LLC
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 165 407-423-7149
      • Tamarac, Florida, Vereinigte Staaten, 33321
        • Rekrutierung
        • D&H Tamarac Research Center
        • Kontakt:
      • Virginia Gardens, Florida, Vereinigte Staaten, 33166
      • Winter Park, Florida, Vereinigte Staaten, 32789
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30328
        • Rekrutierung
        • Clinical Integrative Research Center of Atlanta
        • Kontakt:
          • Telefonnummer: 678-705-7341
      • Atlanta, Georgia, Vereinigte Staaten, 30318
      • Decatur, Georgia, Vereinigte Staaten, 30030
        • Rekrutierung
        • CenExcel iResearch, LLC
        • Kontakt:
          • Telefonnummer: 404-537-1281
      • Savannah, Georgia, Vereinigte Staaten, 31405
        • Rekrutierung
        • CenExel iResearch, LLC.
        • Kontakt:
          • Telefonnummer: 912-744-0800
    • Indiana
      • Evansville, Indiana, Vereinigte Staaten, 47715
        • Beendet
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Vereinigte Staaten, 40004
        • Rekrutierung
        • Kentucky Pediatric/Adult Research
        • Kontakt:
      • Owensboro, Kentucky, Vereinigte Staaten, 42301
        • Beendet
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70115
        • Beendet
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Vereinigte Staaten, 70769
        • Rekrutierung
        • DelRicht Research
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21205
        • Rekrutierung
        • Kennedy Krieger Institute
        • Kontakt:
          • Telefonnummer: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02445
    • Michigan
      • Bloomfield Hills, Michigan, Vereinigte Staaten, 48302
        • Rekrutierung
        • Neurobehavioral Medicine Group
        • Kontakt:
    • Mississippi
      • Flowood, Mississippi, Vereinigte Staaten, 39232
        • Rekrutierung
        • Precise Research Centers
        • Kontakt:
          • Telefonnummer: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89128
        • Rekrutierung
        • Clinical Research of Southern Nevada, LLC.
        • Kontakt:
    • New Jersey
      • Berlin, New Jersey, Vereinigte Staaten, 08009
        • Zurückgezogen
        • Hassman Research Institute
      • Irvington, New Jersey, Vereinigte Staaten, 07111
      • Neptune City, New Jersey, Vereinigte Staaten, 07753
        • Rekrutierung
        • Jersey Shore University Medical Center
        • Kontakt:
    • New York
      • New York, New York, Vereinigte Staaten, 10028
        • Zurückgezogen
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27705
        • Rekrutierung
        • Duke University
        • Kontakt:
          • Telefonnummer: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45229
        • Rekrutierung
        • Cincinnati Children's Hospital and Medical Center
        • Kontakt:
      • West Chester, Ohio, Vereinigte Staaten, 45069
        • Zurückgezogen
        • CincyScience
    • Oregon
      • Gresham, Oregon, Vereinigte Staaten, 97030
        • Rekrutierung
        • Cyn3rgy Research
        • Kontakt:
    • Pennsylvania
      • Hershey, Pennsylvania, Vereinigte Staaten, 17033
        • Rekrutierung
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Vereinigte Staaten, 29405
      • Summerville, South Carolina, Vereinigte Staaten, 29486
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten, 38119
        • Rekrutierung
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Telefonnummer: 901-843-1045
    • Texas
      • Bellaire, Texas, Vereinigte Staaten, 77401
        • Zurückgezogen
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Vereinigte Staaten, 75230
        • Beendet
        • Javara
      • Plano, Texas, Vereinigte Staaten, 75093
        • Rekrutierung
        • AIM Trials, LLC
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 214-856-2778
      • The Woodlands, Texas, Vereinigte Staaten, 77381
    • Virginia
      • Petersburg, Virginia, Vereinigte Staaten, 23805
      • Richmond, Virginia, Vereinigte Staaten, 23220
        • Rekrutierung
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Kontakt:
          • Telefonnummer: 804-628-8736

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

4 Jahre bis 5 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo

Placebo, qd

Placebo will be administered once daily

Experimental: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Andere Namen:
  • SPN-812

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Zeitfenster: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Zeitfenster: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Zeitfenster: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. März 2024

Primärer Abschluss (Geschätzt)

1. Januar 2028

Studienabschluss (Geschätzt)

1. Januar 2028

Studienanmeldedaten

Zuerst eingereicht

26. Februar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. März 2021

Zuerst gepostet (Tatsächlich)

4. März 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren